Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate.
J Org Chem
; 86(7): 5065-5072, 2021 04 02.
Article
in English
| MEDLINE | ID: covidwho-1139704
ABSTRACT
Currently, remdesivir is the first and only FDA-approved antiviral drug for COVID-19 treatment. Adequate supplies of remdesivir are highly warranted to cope with this global public health crisis. Herein, we report a Weinreb amide approach for preparing the key intermediate of remdesivir in the glycosylation step where overaddition side reactions are eliminated. Starting from 2,3,5-tri-O-benzyl-d-ribonolactone, the preferred route consisting of three sequential steps (Weinreb amidation, O-TMS protection, and Grignard addition) enables a high-yield (65%) synthesis of this intermediate at a kilogram scale. In particular, the undesirable PhMgCl used in previous methods was successfully replaced by MeMgBr. This approach proved to be suitable for the scalable production of the key remdesivir intermediate.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Adenosine Monophosphate
/
Alanine
/
Amides
Language:
English
Journal:
J Org Chem
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS